Navigation Links
Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Date:6/3/2008

- Study Published in Journal Molecular Vision - - Results Show Good Distribution of Bevasiranib to Retina and RPE Cells

after a Single Intravitreal Injection -

MIAMI, June 3 /PRNewswire-FirstCall/ -- OPKO Health, Inc. (Amex: OPK) today announced that a study published in the peer-reviewed journal Molecular Vision demonstrates that bevasiranib, its siRNA (small interfering RNA) agent is distributed throughout the eye, including extensive uptake into the retina. In two tissue distribution and pharmacokinetic studies in rabbits, results showed that bevasiranib was present in the retina and in targeted retinal pigment epithelium (RPE) cells following intravitreal injection. Bevasiranib is a gene-silencing agent designed to shut down the production of vascular endothelial growth factor (VEGF), a primary cause of the new blood vessel growth, or neovascularization, associated with vision loss in patients with wet age-related macular degeneration, or wet AMD. The efficacy and safety of bevasiranib are currently being assessed in the COBALT study, an international Phase III trial for the treatment of wet AMD.

"Importantly, these data indicate that following intravitreal injection, bevasiranib distributes to the ocular structures relevant to the VEGF-induced neovascularization associated with vision loss in wet AMD, and we believe this animal data provides support for the use of bevasiranib in our ongoing pivotal Phase III trial for the treatment of wet AMD," said Samuel Reich, Executive Vice President of OPKO Ophthalmics. "It is noteworthy that bevasiranib was distributed to the RPE cells, since we believe that even a fraction of the tissue-associated bevasiranib entering the RPE cell is likely to be ef
'/>"/>

SOURCE OPKO Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
2. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
3. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
4. Newly Approved HIV Drug Shows Great Promise
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
11. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pa. , July 25, 2014  AMETEK, Inc. ... of Kurtis L. Goos as Vice President ... Materials, Interconnects and Packaging (EMIP) Division. "I ... extensive general management and business development experience, especially in ... make important contributions to the continued growth and success ...
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... a corporate update and report second quarter 2014 financial ... Friday, August 1, 2014. That same day, Arena will ... Eastern Time (5:30 a.m. Pacific Time). ... for domestic callers and 914.495.8552 for international callers. Please ...
(Date:7/24/2014)... , July 24, 2014  PTC Therapeutics, Inc. ... Company will host a webcast conference call to report ... update on the company,s business and outlook on Thursday, ... opening of the market. The call ... (973) 935-8152 (international) five minutes prior to the start ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... OSLO, Norway, October 31, 2011 Oslo ... oncology. The true strength of the Norwegian cluster lies ... than the ones available to cancer patients today. ... cluster within the field of oncology, dedicated to accelerating ...
... Inc. (ARKRAY) announced today that the GLUCOCARD® Vital and ... (DoD) Uniform Formulary.  The DoD Pharmacy and Therapeutic committee ... 01 Blood Glucose Meters as the first and second ... of service as noted by the Uniform Formulary Beneficiary ...
Cached Medicine Technology:Expanding Norwegian Cluster of Excellence Dedicated to Oncology 2Expanding Norwegian Cluster of Excellence Dedicated to Oncology 3ARKRAY's GLUCOCARD® Vital and 01 Blood Glucose Meters are now on the Department of Defense Uniform Formulary. 2
(Date:7/26/2014)... July 26, 2014 The birth control ... Mirena IUD contraceptive of new legal information on the ... showing the number of lawsuits pending for July alleging ... free resource for those using popular prescription drugs and ... recalls, studies and legal news all in one place, ...
(Date:7/25/2014)... In recent years, men have become more ... the symptoms associated with age-related testosterone decline. Amid concerns about ... new case study from Renew Man helps to ... using bioidentical hormones. , The case study centers around ... found himself beginning to feel the effects of age-related hormonal ...
(Date:7/25/2014)... As reported by the New Orleans Advocate in ... (7/3), the state of Louisiana has recently seen a large ... cocaine. Officials believe the increase is due to a misconception ... marijuana. However, both doctors and police confirm that that belief ... call it “poison,” doctors have acknowledged that the Louisiana Poison ...
(Date:7/25/2014)... Sport Court® provided and ... Nike National Invitational Tournament (NIT) in Chicago at ... National Tournament (USJN) in Washington D.C. at the ... these prestigious national tournaments included 44 Sport Court Maple ... playing surface at McCormick Place for the NIT, and ...
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 The ... Family Fun Fest on Sunday, July 27 at Discovery ... franchises include Memorial, Copperfield, Katy, Pearland, Friendswood, Spring, The ... in The Heights. , “We’re thrilled to be ... year,” said Heather Belcher who owns the Sugarland-Missouri City ...
Breaking Medicine News(10 mins):Health News:DrugNews Adds Latest Court Updates on Mirena IUD Lawsuits 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2
... Several years ago, scientists at Beth Israel Deaconess Medical ... regarding the Akt molecular pathway, a popular target for ... protein Akt1 was actively preventing cancer cells ... was actually promoting breast cancer cell migration. And, ...
... be one of the leading causes of oral cancer, ... experimental animals has traditionally been limited to examining the ... rather than on observing the effects of carcinogens that ... completed study conducted collaboratively by Dr. Joseph Guttenplan, a ...
... for building new organs to replace damaged livers, blood vessels ... cells grown in a lab dish to form 3-D shapes ... of Health Sciences and Technology (HST) have come up with ... cells in cubes and arranging them into 3-D structures, just ...
... strong, healthy bones. But new research from North Carolina ... the earliest days of life could have a more ... obesity than previously thought. During an 18-day trial ... levels of bone density and strength in 12 piglets ...
... physical competition, not attraction, was central in winning ... State anthropologist., "There is sexual competition in many ... professor of biological anthropology. Many researchers have ... sexual selection. They thought that people,s mating success ...
... ... (NWS), a leading provider of water conservation and water management services, was recently awarded ... ... 2010 -- National Water Services, Inc. (NWS), a leading provider of ...
Cached Medicine News:Health News:Study identifies 1 of the mechanisms behind breast cancer metastasis 2Health News:NYU College of Dentistry, Penn State develop new model for investigating tobacco/oral cancer link 2Health News:Tissue engineers create a new way to assemble artificial tissues 2Health News:Tissue engineers create a new way to assemble artificial tissues 3Health News:Calcium in early life may prevent obesity later 2Health News:It was brawn over beauty in human mating competition 2Health News:National Water Services, Inc. Receives WBE Certification 2
PDA format of the well-known standard antimicrobial reference....
PDA application providing a complete guide for the diagnosis and management of electrolyte disorders....
Contains the most common procedures from all orthopedic sub-specialties organized by body area....
Consists of the print and PDA versions of Harrison's Manual of Medicine 15th Edition. Provides high-end medical content via PDA....
Medicine Products: